|
Antitumor activity
|
All
|
10-20% (n=35)
|
> 20% (n=13)
|
|---|
|
Objective response
|
39 (81.3, 70.2-92.3)
|
26 (74.3, 56.7-87.5)
|
13 (100, 75.3-100)
|
|
Best overall response
|
|
Complete response
|
5 (10.4)
|
5 (14.3)
|
0 (0)
|
|
Partial response
|
34 (70.8)
|
21 (60.0)
|
13 (100)
|
|
Stable disease
|
5 (10.4)
|
5 (14.3)
|
0 (0)
|
|
Progressive disease
|
2 (4.2)
|
2 (5.7)
|
0 (0)
|
|
Unknown
|
2 (4.2)*
|
2 (5.7)
|
0 (0)
|
- Data are presented as No. (%, 95% CI) or No. (%)
- Responses were assessed in accordance with RECIST version 1.1. Only confirmed responses were included
- *Two patients exempted post-baseline efficacy assessments
